The Rockefeller University – Celldex has licensed intellectual property from Rockefeller to target the DEC-205 family of mannose receptors in human dendritic cells, leveraging discoveries from the laboratories of Professor Ralph Steinman and Michel Nussenzweig. Professors Steinman and Nussenzweig also sit on our Scientific Advisory Board. DEC-205 is a key receptor for certain antigen processing pathways, and having access to this IP greatly enhances our ability to develop highly-targeted immunotherapies.
Celldex is also collaborating with Rockefeller to develop CDX-2401, a novel vaccine against HIV, the virus known to cause AIDS. This project is supported through a $14 million grant from the Grand Challenges for Global Health program within the Bill & Melinda Gates Foundation. The project is using the same human antibodies to DEC-205 receptors to selectively initiate robust immune responses against specifically selected HIV antigens.
DCVax-001 is a recombinant protein vaccine designed to prevent and potentially treat human immunodeficiency virus (HIV) infection. The vaccine is composed of a fusion protein containing a human monoclonal antibody specific for the dendritic cell receptor, DEC-205 (CD205), and the HIV gag p24 protein. The vaccine is designed to target HIV antigens directly to endocytic pathways in dendritic cells (DCs) that allow for efficient processing and presentation of multiple HIV peptides on both MHC class I and II products, which will induce HIV-specific CD8+ and CD4+ T cells. This vaccine candidate must be combined with appropriate immunostimulants (adjuvants) to induce immunity to the antigen. In the proposed clinical trial we will use poly ICLC (Hiltonol) from Oncovir, Inc as the adjuvant.
Estimated Enrollment: 45
Study Start Date: May 2010
Estimated Study Completion Date: May 2013
Estimated Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)